Doxorubicin + ifosfamide (soft tissue sarcoma, AI regimen)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-DOXORUBICIN DRUG-IFOSFAMIDE DRUG-MESNA |
|---|
| ID | REG-DOXORUBICIN-IFOSFAMIDE-STS |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-05-04 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | None declared |
Used By
Indication
IND-STS-ADVANCED-1L-AI- IND-STS-ADVANCED-1L-AI
Regimen
REG-DOXORUBICIN-STS- Doxorubicin monotherapy (soft tissue sarcoma)